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Abstract
Elucidating the sites and mechanisms of sRAGE action in the healthy state is vital to better understand the biological
importance of the receptor for advanced glycation end products (RAGE). Previous studies in animal models of disease have
demonstrated that exogenous sRAGE has an anti-inflammatory effect, which has been reasoned to arise from sequestration
of pro-inflammatory ligands away from membrane-bound RAGE isoforms. We show here that sRAGE exhibits in vitro
binding with high affinity and reversibly to extracellular matrix components collagen I, collagen IV, and laminin. Soluble
RAGE administered intratracheally, intravenously, or intraperitoneally, does not distribute in a specific fashion to any healthy
mouse tissue, suggesting against the existence of accessible sRAGE sinks and receptors in the healthy mouse. Intratracheal
administration is the only effective means of delivering exogenous sRAGE to the lung, the organ in which RAGE is most
highly expressed; clearance of sRAGE from lung does not differ appreciably from that of albumin.
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Introduction
Advanced glycation end products (AGEs) are proteins or lipids
with sugar moieties incorporated via non-enzymatic organic
reactions, such as the Maillard reaction. Normally generated
endogenously at low levels, AGE formation is greatly amplified in
the hyperglycemic and oxidative state in diabetes. Although at the
time of RAGE’s discovery other proteins were known to mediate
AGE uptake by phagocytic cells [1,2], it was only with the
discovery of endothelial expression of RAGE that an elegant
mechanism relating elevated AGEs to vascular complications of
diabetes was in place [3,4]. Research since then has shown RAGE
to be an immunoglobulin superfamily receptor which binds and
signals in response to a vast array of endogenous mediators,
including amphoterin (HMGB1) [5,6], amyloid beta [7], calgra-
nulins (S100 proteins) [8,9,10], and the integrin CD11b (Mac-1)
[11,12]. It is therefore not surprising that this protein is now
known to be an important player in a number of disease processes
in humans and animal models, including cardiomyopathy [8],
neurodegeneration [13], and tumor invasion [14]. The rich body
of literature establishing RAGE’s role as a pattern recognition
receptor in a broad spectrum of inflammatory disease processes
notwithstanding, its function in the healthy state remains nebulous.
RAGE exists as two major isoforms: a membrane form of
RAGE, thought to drive downstream inflammatory cascades, and
its soluble counterpart, sRAGE, which has been shown in most
disease models to have a contravening, salutary effect: sRAGE acts
as a decoy receptor by sequestering ligands away from the
membrane isoform, thereby inhibiting inflammation. Substantial
evidence has been presented in support of this model of RAGE
biology [15,16,17,18]. Expression profiling has demonstrated that
RAGE is expressed in the healthy lung at overwhelmingly greater
levels than in any other tissue assayed [12,19,20]. Furthermore,
numerous studies have shown that pulmonary RAGE is primarily
expressed on the basolateral surface of type I alveolar epithelial
cells [21,22,23]. This would suggest that one or both isoforms of
RAGE have an important function in pulmonary homeostasis,
most likely as a sensor of environmental cues or as a mediator of
cell adhesion to underlying basement membrane. Indeed, RAGE’s
affinity for heparin (which is exploited in its purification), as well as
the observation made by other investigators of specific binding by
RAGE-expressing cells to ECM-coated surfaces [24], indicates
that there is already substantial evidence for RAGE binding to
ECM components. Whether RAGE binds to ECM directly or via
intermediary macromolecules is unknown, as is the identity of the
particular ECM proteins that interact with RAGE.
Soluble RAGE has been administered as a therapeutic agent in
a number of animal models of disease and has in most cases been
shown to have a beneficial effect [25,26,27,28,29,30,31,32]. While
this is usually explained through allusion to a decoy mechanism,
which has garnered much supportive evidence in the form of in
vitro competitive inhibition studies [33], sRAGE’s anti-inflamma-
tory effects could also arise from ligation of an as yet unidentified
receptor. Furthermore, the affinity of RAGE to ECM [24]
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suggests that the latter could serve as a sink for endogenously-shed
or exogenously-administered sRAGE, in much the same way that
ECM retains growth factors such as FGF. To address these
hypotheses, as well as answer the more practical question of which
delivery method would best exploit sRAGE’s therapeutic potential
in models of lung disease, radiolabeled sRAGE clearance studies
were undertaken to probe for sRAGE binding partners and sites of
distribution in vivo.
Experimental Procedures
Ethics statement
Animal experiments were performed in accordance with a
protocol (protocol number: 1004847) reviewed and approved by
the Institutional Animal Care and Use Committee at the
University of Pittsburgh. All effort was made to minimize suffering
during treatments, and surgery was performed following anesthe-
tization with sodium pentobarbital. Human lung tissue used in
preparing purified proteins, including sRAGE, was obtained from
autopsies performed at the University of Pittsburgh. Approval for
this was obtained from the University of Pittsburgh Committee for
Oversight of Research and Clinical Training Involving Decedents
(CORID). All autopsy consent forms at the University include a
statement that indicates that autopsy tissue may be used for
research, and the Committee has indicated that additional consent
is not required and that our use of such tissue for protein
purification is approved (CORID No. 266).
sRAGE purification from lung, endotoxin removal,
concentration and biologic activity determination
Soluble RAGE was purified from mouse and human lungs
according to methods previously described [34,35]. Soluble
RAGE was rendered free of detectable endotoxin (,5 EU/kg
mouse) using Detoxi-Gel polymyxin B resin (Thermo Scientific)
per manufacturer’s instructions. Mouse sRAGE concentration was
determined using the molar extinction coefficient and absorbance
at 280 nm (see below). Following purification of mouse sRAGE,
biologic activity was tested and confirmed using HMGB1
concentration-dependent binding as a marker of molecular
integrity, according to previously described methods [19,36] (data
not shown).
sRAGE molar extinction coefficient determination
The concentration of mouse or human RAGE was determined
by quantitative amino acid analysis. The analyses were performed
in triplicate with approximately 2 mg of purified mouse or human
soluble RAGE. The samples were dried in 500-ml polypropylene
vials, the lids were punctured and the vials placed in a 25-ml glass
vial equipped with a MinInert valve (Pierce Biotechnology). A total
of 200 ml 6 N HCl containing 0.1% phenol was placed in the
bottom and the glass was purged with argon before vacuum was
applied. The samples were incubated at 110uC for 18 h. The
samples were subsequently re-dissolved in 50 ml of 0.2 M sodium
citrate loading buffer at pH 2.2 (Biochrom, Cambridge, UK),
transferred into microvials and loaded onto a BioChrom 30 amino
acid analyzer (Biochrom). Data analysis was performed using in-
house developed software. The extinction coefficients were
calculated based on the determined protein concentrations and
the UV absorbance at 280 nm.
Biolayer interferometry
Biolayer interferometry (BLI) was performed on a ForteBIO
Octet (Menlo Park, CA) to determine the kinetics of RAGE
binding to collagen I, collagen IV, laminin, and fibronectin (all
from Sigma) per manufacturer’s instructions and published
methods [37,38]. Purified mouse soluble RAGE was conjugated
to amine-reactive sensor tips. The tips were then transferred into
wells containing the matrix protein of interest in varying
concentrations. Binding was measured as a deflection in the
wavelength of light passing through the sensor. Following 1800 s
of incubation, the RAGE-coated sensor tips were then transferred
to PBS to allow dissociation. In order to confirm specificity of the
binding, reciprocal binding studies were performed with extracel-
lular matrix proteins coupled to the sensor, with sRAGE in
solution. Binding curves were analyzed using the ForteBIO
software, which performs a global fit according to the 1:1
Langmuir model in order to obtain the kinetic rate constants for
each set of interaction conditions [37].
Radiolabeling of mouse serum albumin and mouse
sRAGE
Chromatographically purified mouse serum albumin (Sigma)
and mouse sRAGE were labeled with Na125I (Perkin Elmer) using
the chloramine T method (Iodination Beads, Pierce) per manu-
facturer’s instructions. To remove residual iodine, both samples
were run over Bio-Spin 6 (Bio-Rad) centrifugation columns and
the eluate was collected. Protein concentration was determined
using the absorbance at a wavelength of 280 nm, the calculated
molar extinction coefficient of mouse sRAGE (see Results), and the
commonly reported mass extinction coefficient of serum albumin
of 0.5261023 mL mg21 cm21. Gamma counting was performed
on a Cobra II auto gamma counter (Packard, Perkin-Elmer) and
activity calculated from disintegrations per minute and counting
efficiency. Samples were analyzed by SDS-PAGE, Coomassie Blue
staining, and autoradiography to assess purity.
Animal studies
All animal experiments were approved by the institutional
animal care and use committee. Eight-week-old male C57BL/6
mice (Charles River) were administered radioiodinated mouse
serum albumin or mouse sRAGE via intratracheal (i.t.), intraper-
Table 1. Mouse and human sRAGE extinction coefficients.
Description Amino acid residues Mass (Da)
Extinction coefficient
(M21 cm21)
Theoretically predictedc extinction
coefficient (M21 cm21)
Mouse sRAGE 22–330a 35742.30 67573 33835
Human sRAGE 23–347b 37939.72 87237 39335
aMouse membrane RAGE has a published sequence length of 402 (NP_031451.2).
bHuman membrane RAGE has a published sequence length of 404 (NP_001127.1).
c[50].
doi:10.1371/journal.pone.0088259.t001
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itoneal (i.p.), or intravenous (i.v.) routes. Each animal received
1 mCi of radiolabeled protein in saline, which corresponded to
,0.6–0.9 mg of mouse serum albumin or ,0.7–1.4 mg of mouse
sRAGE; for intraperitoneal/intravenous and intratracheal treat-
ments, the treatment volumes were 200 mL and 70 mL, respec-
tively. Mice were sacrificed at 1, 2, 4, and 12 hours after the
treatment, with 4–5 mice used per treatment group (the variables
being test vs. control, route of administration, and time of sacrifice
post-treatment). Mice were euthanized with i.p. sodium pento-
barbital, urine was collected, and blood drawn from the right
ventricle of the heart. The pulmonary circulation was transcar-
dially perfused with saline until the lungs blanched. Then, the
systemic circulation was transcardially perfused with saline until
the liver and kidneys blanched. In 3 mice of each group, the lungs
Figure 1. RAGE binds with high affinity to collagen I, collagen IV, and laminin, but not to fibronectin. Soluble RAGE affinity for collagen
I, collagen IV, laminin, and fibronectin was assessed by biolayer interferometry. Soluble RAGE was conjugated to an amine-reactive sensor and dipped
into solutions containing collagen I (A), collagen IV (B), laminin (E), or fibronectin (F) for 1800 s, at which point dissociation was initiated by washing in
PBS. Binding was measured as a deflection in the wavelength of light passing through the sensor; affinities were calculated by fitting the curves with
analysis software. Reciprocal binding was studied with collagen I (C) and collagen IV (D) conjugated to the sensor and sRAGE in solution. Laminin and
fibronectin could not be conjugated to the sensor.
doi:10.1371/journal.pone.0088259.g001
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were inflation-fixed with 800 mL of 10% neutral buffered formalin
(NBF) and the systemic circulation was perfused with 10% NBF, as
well. Following organ harvest, the stomach, small intestine, and
colon were thoroughly flushed with saline before weighing and
gamma counting.
Tissue, fluid, and organ processing
The following tissues, fluids, and organs were assayed: blood,
urine, stomach, small intestine, colon, bladder, kidneys, pancreas,
spleen, liver, skeletal muscle, femur, thymus, heart, lungs, and
brain. These were dispensed into previously tared gamma
counting vials and weighed. Samples were kept on ice until ready
Table 2. Kinetics of binding of extracellular matrix proteins in solution to solid-phase sRAGE.
Analyte Concentration (nM) kon (M
21 s21) koff (s
21) KD (nM)
Collagen I 3.87 NDa ND ND
19.40 5.186104 1.8261024 3.51
38.70 3.506104 5.6661025 1.62
58.10 1.436104 2.6361025 1.84
Collagen IV 6.94 ND ND ND
34.70 2.446104 6.2661025 2.57
69.40 2.156104 7.7261025 3.59
104.00 1.676104 8.1061025 4.81
Laminin 11.10 7.546104 1.9161024 2.53
22.20 1.066105 1.0261024 0.96
33.30 1.366105 8.0261025 0.59
44.40 1.716105 1.0861024 0.63
Fibronectin 6.25 ND ND ND
12.50 ND ND ND
18.75 ND ND ND
25.00 ND ND ND
aNot determined due to undetectable specific binding.
doi:10.1371/journal.pone.0088259.t002
Figure 2. sRAGE and MSA used in biodistribution and clearance studies are very pure. (A) SDS-PAGE separation and Coomassie Brilliant
Blue staining of ,2.5 mg of MSA or mouse sRAGE preparations used for radiolabeling. (B) SDS-PAGE separation and gel autoradiography of 125I-
labeled MSA and mouse sRAGE.
doi:10.1371/journal.pone.0088259.g002
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for counting. Following gamma counting, unfixed samples were
transferred to cryotubes and flash frozen in liquid nitrogen and
stored at 280uC; fixed organs, excepting bone, were placed in
cassettes and agitated in a large volume of 10% NBF overnight;
bones were decalcified in Cal-Rite (Richard Allen Scientific)
overnight. Following fixation, samples were dehydrated through
an ethanol series, pre-cleared in xylenes, and embedded in
paraffin.
SDS-PAGE and autoradiography of organ homogenates
Frozen lungs, kidneys, livers, stomachs, and pancreata of mice
that were treated i.t., i.p., or i.v. with radiolabeled mouse serum
albumin or mouse sRAGE were homogenized in 1.5 mL ice-cold
homogenization buffer (50 mM Tris-HCl, 150 mM NaCl,
pH 7.4) containing protease inhibitors (100 mM DCI, 1 mM
1,10-phenanthroline, and 10 mM E-64). The homogenates were
centrifuged at 200006g for 20 minutes at 4uC. Supernatants were
collected and 60 mL of each sample was denatured and reduced
with SDS and DTT and boiled for 3 minutes, then shock cooled
on ice. Proteins were separated by SDS-PAGE and detected by
Coomassie Blue staining and autoradiography to assess radiola-
beled protein degradation as a function of time.
Slide preparation and autoradiographic analysis
Paraffin blocks were sectioned at a thickness of 5 mm and tissue
sections were mounted on glass slides and air-dried. Deparaffini-
zation was accomplished with heat and xylenes, and the tissue was
rehydrated through an ethanol series. Autoradiography emulsion
NBT (Eastman Kodak, Rochester, NY) was heated to 42uC. Slides
were dipped in molten emulsion, briefly air dried, and stored in
light-insulated slide boxes with desiccant. Slides were stored at 4uC
in the dark for 3–5 weeks. Following incubation, the slides were
developed in D-19 developer and fixed (developer and fixer both
from Eastman Kodak), then washed, stained with hematoxylin and
eosin, dehydrated into xylenes, and coverslipped with Permount
(Fisher). Slides were examined using an Olympus BH-2 micro-
scope equipped with an Olympus DP12 camera.
Regression and statistical analysis
Quantitative data were analyzed using GraphPad Prism 5
(GraphPad Software Inc., La Jolla, CA). Exponential decay fitting
for radioactive tracer clearance was performed using this program,
as were statistical analyses. Comparisons were conducted with
Student’s t-test. Values are reported as mean 6 standard error of
the mean. A p-value of ,0.05 was considered statistically
Figure 3. Organ biodistribution of intravenously-administered sRAGE or MSA in mice. Organ biodistribution of mouse sRAGE or MSA (A)
1 hour, (B) 2 hours, (C) 4 hours, and (D) 12 hours after intravenous injection of ,1 mCi of tracer, corresponding to ,0.6–1.4 mg of radiolabeled
protein. Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0088259.g003
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significant and is indicated by an asterisk on graphical represen-
tations of the data.
Results
Determination of sRAGE molar extinction coefficient
Because sRAGE is widely used as a therapeutic in animal
models of disease, and in view of numerous studies that have
aimed to quantitatively characterize sRAGE interactions with
ligands, the molar extinction coefficients of mouse and human
sRAGE (in both cases with the 21–22 residue signal peptide
cleaved off) at 280 nm light wavelength and 22uC, were
determined. Due to interspecies variation in glycosylation and
intrinsic characteristics unique to the protein, these coefficients are
expected to permit more accurate quantitation than was possible
based on colorimetric absorbance-shift methods. Table 1 summa-
rizes the results, which demonstrate a marked discrepancy from
the theoretically predicted molar extinction coefficients. This is
most likely related to the contribution of carbohydrate moieties to
the measured absorbances of mouse and human sRAGE.
Determination of sRAGE affinities for extracellular matrix
proteins
Studies by others have indicated that expression of mRAGE on
cultured cells augments cell affinity to surfaces coated with ECM
proteins [24]. This interaction was demonstrated to be specific,
although whether it was direct or mediated by adaptor or co-
expressed proteins was never clarified. In vitro binding studies with
blends of purified sRAGE and ECM proteins demonstrate that
sRAGE binds with very high affinity to collagen I, collagen IV,
and laminin. Mean dissociation constant (KD) values of 2.32 nM
for collagen I, 3.67 nM for collagen IV, and 1.18 nM for laminin,
were obtained for studies with sRAGE in the solid phase (Fig. 1A–
C). Collagen I and IV affinities determined with sRAGE in the
immobile phase were confirmed by reciprocal binding studies with
sRAGE in the mobile phase, thus demonstrating specificity of the
measured interaction. Laminin and fibronectin, however, could
not be conjugated to the surface of the sensor. Importantly, no
specific binding of sRAGE to fibronectin could be demonstrated
(Fig. 1D). Table 2 summarizes the results.
Figure 4. Organ biodistribution of intraperitoneally-administered sRAGE or MSA in mice. Organ biodistribution of mouse sRAGE or MSA
(A) 1 hour, (B) 2 hours, (C) 4 hours, and (D) 12 hours after intraperitoneal injection of ,1 mCi of tracer, corresponding to ,0.6–1.4 mg of radiolabeled
protein. Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0088259.g004
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Determination of sRAGE organ biodistribution
To determine the most efficacious means of delivering sRAGE
to the lung, clearance studies were performed with radiolabeled
sRAGE or radiolabeled control MSA given via three common
routes of administration. To confirm that the proteins being
administered were adequately pure, SDS-PAGE and Coomassie
Brilliant Blue gel staining were performed and indeed failed to
detect the presence of proteins other than MSA (,69 kDa) and
sRAGE (,42 kDa), which migrated as expected (Fig. 2A).
Following radiolabeling, SDS-PAGE and gel autoradiography
were performed to confirm 125I incorporation into sRAGE or
MSA and removal of free iodine (Fig. 2B). Slight radiolabeled
impurities are evident in both preparations but are unlikely to
account for more than several percents of the total protein load.
Small quantities of radiotracer were used so as to minimize any
potential effect of these bioactive proteins on physiology.
Intravenous (Fig. 3) and i.p. (Fig. 4) injections failed to deliver
an appreciable quantity of sRAGE or MSA to the lung within the
12-hour window surveyed, by which time extensive renal
clearance had already occurred. In contrast, i.t. instillation
(Fig. 5) was very efficacious at delivering sRAGE and MSA to
the lung, and was in fact the only feasible means of doing so.
Characterization of sRAGE clearance from the lung and
other organs
To investigate the kinetics of exogenous protein clearance the
biodistribution data for intravenous, intraperitoneal, and intratra-
cheal administration of 125I-labeled sRAGE (and 125I-labeled
MSA, for the case of i.t. instillation) was plotted with respect to
time, and mono-exponential decay fitting was performed. For i.v.
administrations, data from the 1 hr time point onwards was used
for fitting; for i.p. and i.t. administrations, where there is a lag time
before the majority of the protein has translocated out of the
peritoneal and pulmonary compartments, data from the 2 hr time
point onwards was used for fitting. Bi-exponential and multi-
exponential fittings were not taken into consideration because
there is insufficient mechanistic understanding at the microscopic
level of the processes by which MSA or sRAGE are cleared from
lung and other organs. The half-lives of sRAGE organ elimina-
tion, determined from the above described nonlinear regression
analyses, are summarized in Table 3. Both MSA and sRAGE
(Fig. 6A, blue and red curves, respectively) were cleared rapidly
from the lung, with half-lives of 2.29 hours for MSA and
2.98 hours for sRAGE. Catabolism is one of many possible
mechanisms of protein clearance. To test whether degradative
processes are involved in or compete with sRAGE clearance from
Figure 5. Organ biodistribution of intratracheally-administered sRAGE or MSA in mice. Organ biodistribution of mouse sRAGE or MSA (A)
1 hour, (B) 2 hours, (C) 4 hours, and (D) 12 hours after intratracheal instillation of ,1 mCi of tracer, corresponding to ,0.6–1.4 mg of radiolabeled
protein. Asterisks indicate statistically significant differences.
doi:10.1371/journal.pone.0088259.g005
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lung, lung homogenates from animals that had received MSA or
sRAGE by i.t. instillation were prepared, and proteins were
separated by SDS-PAGE. Gel autoradiography was subsequently
performed to detect the radiolabeled species present. Comparison
with the gel autoradiograph of the 125I-labeled purified proteins
(Fig. 2B) indicates that neither MSA nor sRAGE undergo
appreciable proteolysis as they are eliminated from normal healthy
lung (Fig. 6B).
Determination of exogenous sRAGE cellular localization
in lung
To determine the pulmonary sites at which sRAGE egress
occurs, autoradiography was performed on sections of lung from
mice given radiolabeled sRAGE by i.t. instillation. Soluble RAGE
and MSA rapidly reach the alveolar compartment and thence the
circulation (Fig. 7). There is no apparent predilection of these
proteins for the bronchial epithelium, type II alveolar epithelial
cells, or alveolar macrophages.
Discussion
Soluble RAGE has been widely utilized as a therapeutic agent
in animal models of inflammatory disease. The mechanism of its
anti-inflammatory action in vitro and in vivo is thought to be that of
ligand sequestration away from cell surface receptors (including
but not limited to membrane RAGE) that activate downstream
inflammatory signaling cascades. The potential for sRAGE
retention in ECM in vivo, as well as the existence of receptors of
which sRAGE is a ligand, has not been adequately studied.
Biolayer interferometry experiments performed on binary mix-
tures of sRAGE and individual ECM components demonstrate
high-affinity reversible binding of sRAGE to collagen I and IV as
well as to laminin, with no observable specific interaction between
sRAGE and fibronectin (Fig. 1). The kinetics of this interaction are
relatively slow, which may be a consequence of the random
orientation of solid-phase conjugated sRAGE reducing the avidity
to ECM proteins, and the formation of sRAGE oligomers in
solution [39] competing with binding to solid-phase ECM
proteins. This represents an advance from previous studies
Table 3. Organ elimination half-life of exogenous mouse sRAGE administered by three different routes.
Organ t1/2 (hrs, i.v.) t1/2 (hrs, i.p.) t1/2 (hrs, i.t.)
Stomach 2.92 5.04 2.98
Small intestine 1.28 2.82 NDa
Colon 1.58 3.46 ND
Bladder ND ND ND
Kidneys 1.75 ND ND
Pancreas 1.87 ND 3.90
Spleen 0.514 5.82 ND
Liver 0.591 ND 2.39
Skeletal muscle ND ND 3.74
Bone 1.65 ND ND
Thymus 2.05 1.95 ND
Heart 2.13 8.95 1.27
Brain 1.78 ND 10.7
Lungs 0.359 1.74 2.98
aNot determined due to ambiguity, interruption, or lack of convergence of fit.
doi:10.1371/journal.pone.0088259.t003
Figure 6. Clearance of intratracheally-administered sRAGE or
MSA from mouse lung is rapid and non-proteolytic. (A)
Exogenous mouse sRAGE or MSA persistence in mouse lung as a
function of time. (B) SDS-PAGE separation and gel autoradiography of
lung homogenates from mice administered i.t. mouse sRAGE or MSA
and sacrificed at the indicated time points thereafter.
doi:10.1371/journal.pone.0088259.g006
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conducted using RAGE-expressing cell lines and coated ECM
[24], for it demonstrates that RAGE-ECM protein interactions
can occur directly and without mediation of bridging molecules or
intracellular scaffolds that would modulate RAGE conformation
and cell surface density. Furthermore, these results suggest that
exogenous sRAGE delivered as a therapeutic may interact with
exposed basement membrane components and thus compete for
ECM binding sites with adhesion proteins expressed on overlying
cells, thus modulating cellular adhesion and function.
Probing for cognate receptors of a ligand of interest may be
accomplished by assessing biodistribution and clearance charac-
teristics of the ligand as compared to those of a suitable control.
MSA was used as a treatment control to distinguish between
specific preferential organ biodistribution due to sRAGE binding
partners and nonspecific preferential organ biodistribution due to
greater vascular density or permeability. The biodistribution
profile of sRAGE and MSA following i.p. (Fig. 3) or i.v. (Fig. 4)
administration would seem to suggest preferential retention of
Figure 7. Clearance of intratracheally-administered sRAGE from mouse lung occurs at the alveolar-capillary interface. Representative
light micrographs/autoradiographs recorded at 206magnification of sections of lung from mice given mouse sRAGE (or MSA, shown for comparison)
i.t. and sacrificed at the indicated time points thereafter. Lung from untreated mice serves as a control for background radiation.
doi:10.1371/journal.pone.0088259.g007
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sRAGE as compared to MSA in a number of organs, including
kidneys, liver, spleen, stomach, small intestine, colon, pancreas,
skeletal muscle, bone, and brain. However, when these two
administration routes were compared to each other and to i.t.
instillation (Fig. 5), no consistent pattern of organ biodistribution
emerged, with the notable exception of sRAGE localization to the
kidneys. Indeed, the observation of transient preferential sRAGE
biodistribution to multiple organs (but with no consistency in this
regard between the various administration routes tested) is unlikely
to reflect sRAGE-binding sites in these organs, but rather to the
more rapid kinetics of transport of sRAGE across intervening
barriers. Soluble RAGE is approximately half the molecular
weight of MSA, with a reported Stokes radius of 2.81 nm for
human sRAGE [40] as compared to a Stokes radius of 3.55 nm
for bovine serum albumin [41]. This has important implications
for paracellular transport, for transport across the medium-sized
(,4–5.5 nm in diameter) and largest (,25 nm in diameter) pores
of the peritoneal membrane [42], as well as for transport across
vascular basement membranes, the theoretical pore sizes of which
may vary depending upon the tissue in question. Thus, with
sRAGE traversing the diffusion barriers to the peripheral tissues
more rapidly than does MSA, a transient apparent discrepancy in
distribution between the two radiolabeled proteins arises. Howev-
er, the preferential biodistribution of sRAGE to the kidneys is
consistent and likely related to the size and charge properties of
sRAGE and MSA. Soluble RAGE binds with high affinity to
heparin and heparan sulfate, the latter of which is abundant in
renal basement membrane. Moreover, sRAGE is sufficiently small
to traverse the glomerular barrier during filtration (the effective
glomerular pore size being ,8 nm) and thus be excreted intact. In
contrast, the negative charge and larger size of albumin restrict it
from being filtered intact, and therefore this protein must be
eliminated via other pathways.
Of three common routes of administration tested, sRAGE can
be delivered to the pulmonary compartment solely via intratra-
cheal instillation (Fig. 5). Other investigators have suggested that
intraperitoneally-administered sRAGE has therapeutic benefit in
mouse models of lung disease [43]. It is possible that in these cases,
pulmonary injury facilitates sRAGE translocation from the
circulation into the lung either through a regulated mechanism
or damage to the pulmonary epithelium and vasculature. Finally,
it is also possible that the low doses (hundreds of nanograms) of
radiolabeled proteins given here fail to recruit low-affinity
transport receptors in the pulmonary vasculature that gain
relevance when much higher doses (dozens of micrograms) of
sRAGE are given i.p. or i.v. These studies are of vital importance
for investigators seeking to better understand RAGE’s contribu-
tion to homeostasis and pathogenesis in diseases of the lung, the
organ in which RAGE is expressed most significantly.
Exogenous sRAGE is rapidly cleared from the lung with
clearance kinetics similar to that of MSA (Fig. 6A). Moreover,
sRAGE remains intact in the lung (Fig. 6B) and effectively
distributes to the alveoli, from whence it translocates into the
circulation (Fig. 7). These results are surprising, as the lung is rich
in many RAGE ligands, including heparin [34], heparan sulfate
[44], collagen I and IV [45], and indeed RAGE itself [40]
(membrane and soluble RAGE displays homo-oligomerization at
low concentrations), all of which are also present in the alveolar
basement membrane and pulmonary interstitium. This indicates
that, despite the abundance of RAGE binding partners in the lung,
in the healthy state these do not act as effective sites of sRAGE
sequestration. It is important to note, however, that a number of
previous studies have found an inverse relationship between
molecular size and lung clearance rate of a variety of molecules
[46,47]. Therefore, as a significantly smaller molecule than
albumin, sRAGE would be expected to demonstrate significantly
faster clearance from lung. That sRAGE clearance is less rapid
than MSA clearance may suggest retardation of sRAGE transport
by transient interactions between sRAGE and its ligands. In this
context it is also worth noting that an alveolar epithelial receptor,
gp60, has been identified as a mediator of albumin uptake and
transcytosis [48]. It is likely that such a designated system for
return of protein into the circulation does not exist for sRAGE,
which would thus have to rely on less rapid mechanisms of egress
such as paracellular transport and fluid-phase endocytosis [49].
Regardless of the microscopic details of protein clearance from the
lung, it is evident from these biodistribution and clearance studies
that, should sRAGE be used as a therapeutic in pulmonary
disease, it must be functionalized to greatly increase half-life or it
must be administered frequently via the airways. These studies
utilized an i.t. instillation approach of sRAGE administration, but
they also suggest that intranasal and nebulized aerosol adminis-
tration would be effective in delivering sRAGE to the pulmonary
compartment.
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